Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELEV Stock Forecast 2025-2026
$0.30
Current Price
$20.23M
Market Cap
Buy 3
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to ELEV Price Targets
+433.3%
To High Target of $1.60
+233.3%
To Median Target of $1.00
+133.3%
To Low Target of $0.70
ELEV Price Momentum
-11.8%
1 Week Change
-9.1%
1 Month Change
-91.7%
1 Year Change
-46.4%
Year-to-Date Change
-93.1%
From 52W High of $4.33
+35.7%
From 52W Low of $0.22
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Elevation Oncology (ELEV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ELEV and similar high-potential opportunities.
Latest ELEV Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, ELEV has a neutral consensus with a median price target of $1.00 (ranging from $0.70 to $1.60). Currently trading at $0.30, the median forecast implies a 233.3% upside. This outlook is supported by 3 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Biren Amin at Piper Sandler, suggesting a 133.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELEV Analyst Ratings
3
Buy
5
Hold
0
Sell
ELEV Price Target Range
Low
$0.70
Average
$1.00
High
$1.60
Current: $0.30
Latest ELEV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELEV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 24, 2025 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Downgrade | $1.00 |
| Mar 21, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Perform | Downgrade | $7.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $1.00 |
| Mar 21, 2025 | Piper Sandler | Biren Amin | Neutral | Downgrade | $0.70 |
| Mar 21, 2025 | Leerink Partners | Andrew Berens | Market Perform | Downgrade | $1.00 |
| Mar 10, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Mar 7, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $5.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jan 3, 2025 | William Blair | Outperform | Initiates | $0.00 | |
| Dec 19, 2024 | JMP Securities | Market Outperform | Reiterates | $0.00 | |
| Dec 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Dec 6, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $5.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jul 15, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
| Jun 28, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
| May 31, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $10.00 |
| May 14, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Initiates | $8.00 |
| May 3, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $8.00 |
| Apr 9, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
Elevation Oncology Inc. (ELEV) Competitors
The following stocks are similar to Elevation Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ELEV
Elevation Oncology
mkt cap
21.36M
Elevation Oncology Inc. (ELEV) Financial Data
Elevation Oncology Inc. has a market capitalization of $20.23M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -77.5%.
Valuation Metrics
Market Cap
$20.23M
Enterprise Value
$-41,821,884
P/E Ratio
0.0x
PEG Ratio
-0.4x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+524.7%
Current Ratio
21.2x
Debt/Equity
51.9x
ROE
-77.5%
ROA
-30.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Elevation Oncology Inc. (ELEV) Business Model
About Elevation Oncology Inc.
What They Do
Develops targeted cancer therapies using precision medicine.
Business Model
Elevation Oncology generates revenue through the research and development of cancer therapies that target specific genetic alterations in patients. By focusing on precision medicine, the company aims to create effective treatments that address unmet medical needs in oncology, potentially leading to partnerships or licensing agreements with larger pharmaceutical companies.
Additional Information
The company plays a significant role in the biotechnology sector, contributing to advancements in cancer research and treatment. Its focus on genetic profiling and targeted interventions positions it well in the rapidly growing field of personalized medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Mr. Joseph J. Ferra Jr.
Country
United States
IPO Year
2020
Website
elevationoncology.comElevation Oncology Inc. (ELEV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
May 09, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
1 day ago
Quick Summary
Elevation Oncology presented preclinical data for EO-1022, a HER3 ADC, at the AACR Annual Meeting. An IND filing is expected in 2026, with cash runway extending into 2H 2026.
Why It Matters
The announcement of preclinical data for EO-1022 and the anticipated IND filing in 2026 highlights potential for future growth, impacting investor confidence and stock performance in Elevation Oncology.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elevation Oncology (Nasdaq: ELEV) announced preclinical data for EO-1022, a HER3 ADC targeting solid tumors. They plan to file an IND application in 2026.
Why It Matters
EO-1022's potential to address unmet needs in solid tumors and its upcoming IND filing could drive future valuation and market interest for Elevation Oncology. Positive data may enhance investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elevation Oncology's EO-1022, a HER3 ADC for solid tumors, will present preclinical data at AACR 2025. An IND application is on track for 2026.
Why It Matters
The acceptance of EO-1022's data presentation signals potential advancements in oncology, which may attract investor interest due to its innovative approach and upcoming IND application.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elevation Oncology, Inc. (ELEV) has decided to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
Why It Matters
Discontinuing EO-3021 signals potential setbacks in Elevation Oncology's pipeline, possibly impacting future revenue and investor confidence in the company's growth prospects.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Elevation Oncology is advancing EO-1022, an HER3 ADC, with preclinical data to be presented at AACR 2025 and plans for an IND filing in 2026. Development of EO-3021 is discontinued. A workforce reduction of 70% is implemented, extending cash runway into 2H 2026.
Why It Matters
The advancement of EO-1022 and extended cash runway indicate potential growth, while discontinuing EO-3021 may streamline focus and reduce losses, impacting future valuations and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ELEV halts development of its lead drug following disappointing results from an early-stage study on its sole clinical-stage drug for gastric cancers.
Why It Matters
ELEV's decision to halt its lead drug's development signals potential financial instability and loss of investor confidence, likely impacting its stock value and future funding prospects.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ELEV Stock
What is Elevation Oncology Inc.'s (ELEV) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Elevation Oncology Inc. (ELEV) has a median price target of $1.00. The highest price target is $1.60 and the lowest is $0.70.
Is ELEV stock a good investment in 2025?
According to current analyst ratings, ELEV has 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELEV stock?
Wall Street analysts predict ELEV stock could reach $1.00 in the next 12 months. This represents a 233.3% increase from the current price of $0.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elevation Oncology Inc.'s business model?
Elevation Oncology generates revenue through the research and development of cancer therapies that target specific genetic alterations in patients. By focusing on precision medicine, the company aims to create effective treatments that address unmet medical needs in oncology, potentially leading to partnerships or licensing agreements with larger pharmaceutical companies.
What is the highest forecasted price for ELEV Elevation Oncology Inc.?
The highest price target for ELEV is $1.60 from at , which represents a 433.3% increase from the current price of $0.30.
What is the lowest forecasted price for ELEV Elevation Oncology Inc.?
The lowest price target for ELEV is $0.70 from Biren Amin at Piper Sandler, which represents a 133.3% increase from the current price of $0.30.
What is the overall ELEV consensus from analysts for Elevation Oncology Inc.?
The overall analyst consensus for ELEV is neutral. Out of 9 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are ELEV stock price projections?
Stock price projections, including those for Elevation Oncology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 3:51 AM UTC